MaxLinear (MXL) has had the highest return between March 10, 2026 and August 10, 2026 by a mid-cap US stock, returning 368.3%.
| ASSET | DATE | % RETURN |
|---|---|---|
MaxLinear (MXL) | 3/10/2026 - 8/10/2026 | 368.33% |
P3 Health Partners (PIII) | 3/10/2026 - 8/10/2026 | 293.88% |
Maase (MAAS) | 3/10/2026 - 8/10/2026 | 217.8% |
Penguin Solutions (PENG) | 3/10/2026 - 8/10/2026 | 216.87% |
Navan, Inc Class A Common Stock (NAVN) | 3/10/2026 - 8/10/2026 | 197.04% |
Oruka Therapeutics (ORKA) | 3/10/2026 - 8/10/2026 | 193.67% |
Hemab Therapeutics Holdings, Inc Common Stock (COAG) | 3/10/2026 - 8/10/2026 | 175.89% |
CareDx (CDNA) | 3/10/2026 - 8/10/2026 | 163.64% |
Uniqure (QURE) | 3/10/2026 - 8/10/2026 | 158.46% |
Aehr Test Systems (AEHR) | 3/10/2026 - 8/10/2026 | 157.16% |
BlackBerry (BB) | 3/10/2026 - 8/10/2026 | 156.57% |
Spyre Therapeutics (SYRE) | 3/10/2026 - 8/10/2026 | 155.32% |
Definium Therapeutics (DFTX) | 3/10/2026 - 8/10/2026 | 149.95% |
Liquidia Technologies (LQDA) | 3/10/2026 - 8/10/2026 | 149.23% |
10X Genomics (TXG) | 3/10/2026 - 8/10/2026 | 147.29% |
Insperity (NSP) | 3/10/2026 - 8/10/2026 | 145.3% |
MBX Biosciences, Inc Common Stock (MBX) | 3/10/2026 - 8/10/2026 | 142.21% |
Twist Bioscience (TWST) | 3/10/2026 - 8/10/2026 | 139.43% |
Butterfly Network (BFLY) | 3/10/2026 - 8/10/2026 | 136.73% |
Pulse Biosciences (PLSE) | 3/10/2026 - 8/10/2026 | 135.61% |
Clover Health Investments (CLOV) | 3/10/2026 - 8/10/2026 | 134.48% |
UroGen Pharma (URGN) | 3/10/2026 - 8/10/2026 | 132.71% |
AMC Entertainment (AMC) | 3/10/2026 - 8/10/2026 | 131.25% |
Veradermics (MANE) | 3/10/2026 - 8/10/2026 | 122.77% |
AXT (AXTI) | 3/10/2026 - 8/10/2026 | 121.62% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.